Trial Profile
A Multicenter Study of Prognosis and the Efficacy Comparison of Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Patients(Clinical Risk Score≥3) of Resectable Colorectal Liver Metastasis
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 17 Mar 2023
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Colorectal cancer; Liver metastases
- Focus Therapeutic Use
- Acronyms PARECEC
- 29 Jan 2021 Status changed from recruiting to completed.
- 07 Jul 2020 Planned End Date changed from 1 Dec 2018 to 30 Dec 2020.
- 07 Jul 2020 Planned primary completion date changed from 1 Sep 2018 to 30 Nov 2020.